NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of P21 in Multiple Myeloma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2015 Jul 10

PMID 26156395

Citations 25

Authors

Junwei Huang

Yi Zhou

Gregory S Thomas

Zhimin Gu

Ye Yang

Hongwei Xu

Guido Tricot

Fenghuang Zhan

Affiliations

Soon will be listed here.

Abstract

Purpose: CKS1B is significantly upregulated in multiple myeloma and associated with poor prognosis. The identification of novel therapies is essential for effective treatment of patients resistant to chemotherapy. The NEDD8 inhibitor MLN4924 selectively targets SCF(Skp2) activation and offers a more specific approach to protein degradation inhibition than total proteasomal inhibition. The goal of this study was to evaluate whether MLN4924 is effective in high CKS1B conditions and identify mechanisms regulating drug potency.

Experimental Design: Bortezomib and MLN4924 sensitivity was assessed through proliferation, viability, clonogenic potential, and senescence induction in cells overexpressing CKS1B. The mechanism for MLN4924 sensitivity was elucidated by immunoblot analysis of SCF(skp) substrates and confirmed by shRNA knockdown. The clinical relevance of the NEDD8 pathway was examined in gene expression profiles (GEP) derived from healthy people, patients with monoclonal gammopathy of undetermined significance (MGUS), and multiple myeloma.

Results: Cells overexpressing CKS1B were resistant to bortezomib but sensitive to MLN4924. Treatment of CKS1B-overexpressing cells with MLN4924 decreased proliferation, clonogenicity, and induced senescence. MLN4924, but not bortezomib, induced stabilization of p21 and knockdown of p21 resulted in loss of MLN4924 sensitivity. Patients with MGUS and multiple myeloma exhibited increased expression of NEDD8 pathway genes relative to normal plasma cells. Multiple myeloma patients with high NEDD8 expression were linked to bortezomib resistance in clinical trials, and had inferior outcomes.

Conclusions: Our data demonstrate that cells with elevated CKS1B expression are resistant to bortezomib but sensitive to MLN4924 and offer a mechanism through the stabilization of p21. These findings provide rationale for targeting the NEDD8 pathway in multiple myeloma patients exhibiting elevated expression of CKS1B. Clin Cancer Res; 21(24); 5532-42. ©2015 AACR.

Citing Articles

Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy.

McAuley N, Cymer I, McAvera R, Hopkins A, Glavey S Eur J Haematol. 2024; 114(3):400-410.

PMID: 39632279 PMC: 11798765. DOI: 10.1111/ejh.14352.

Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

Li F, Liu J, Fu Y Curr Treat Options Oncol. 2024; 25(11):1354-1365.

PMID: 39432172 DOI: 10.1007/s11864-024-01273-6.

Authentication and validation of key genes in the treatment of atopic dermatitis with Runfuzhiyang powder: combined RNA-seq, bioinformatics analysis, and experimental research.

Lin Y, Xiong G, Xia X, Yin Z, Zou X, Zhang X Front Genet. 2024; 15:1335093.

PMID: 39149589 PMC: 11324508. DOI: 10.3389/fgene.2024.1335093.

Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Li X, Li W, Zhang Y, Xu L, Song Y Genes Dis. 2024; 11(5):101150.

PMID: 38947742 PMC: 11214299. DOI: 10.1016/j.gendis.2023.101150.

Secretome of Cancer-Associated Fibroblasts (CAFs) Influences Drug Sensitivity in Cancer Cells.

Lau R, Yu L, Roumeliotis T, Stewart A, Pickard L, Choudhary J J Proteome Res. 2024; 23(6):2160-2168.

PMID: 38767394 PMC: 11165579. DOI: 10.1021/acs.jproteome.4c00112.

References

Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng W, Roels S . Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2006; 109(8):3177-88. DOI: 10.1182/blood-2006-09-044974. View

Chang H, Trieu Y, Qi X, Xu W, Stewart K, Reece D . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2006; 31(6):779-82. DOI: 10.1016/j.leukres.2006.08.002. View

Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B . Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res. 2007; 67(22):10899-909. DOI: 10.1158/0008-5472.CAN-07-2837. View

Oerlemans R, Franke N, Assaraf Y, Cloos J, van Zantwijk I, Berkers C . Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112(6):2489-99. DOI: 10.1182/blood-2007-08-104950. View

Saha A, Deshaies R . Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell. 2008; 32(1):21-31. PMC: 2644375. DOI: 10.1016/j.molcel.2008.08.021. View

Xiong W, Wu X, Starnes S, Johnson S, Haessler J, Wang S . An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008; 112(10):4235-46. PMC: 2581979. DOI: 10.1182/blood-2007-10-119123. View

Escoubet-Lozach L, Lin I, Jensen-Pergakes K, Brady H, Gandhi A, Schafer P . Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009; 69(18):7347-56. DOI: 10.1158/0008-5472.CAN-08-4898. View

Lin H, Chen Z, Wang G, Nardella C, Lee S, Chan C . Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010; 464(7287):374-9. PMC: 2928066. DOI: 10.1038/nature08815. View

Wang X, Xu J, Ju S, Ni H, Zhu J, Wang H . Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem. 2010; 43(7-8):655-60. DOI: 10.1016/j.clinbiochem.2010.02.004. View

10.

Krishnan A, Nair S, Pillai M . Loss of cks1 homeostasis deregulates cell division cycle. J Cell Mol Med. 2009; 14(1-2):154-64. PMC: 3837597. DOI: 10.1111/j.1582-4934.2009.00698.x. View

11.

Zolota V, Tzelepi V, Leotsinidis M, Zili P, Panagopoulos N, Dougenis D . Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma. J Surg Res. 2009; 164(2):256-65. DOI: 10.1016/j.jss.2009.03.035. View

12.

Lin J, Milhollen M, Smith P, Narayanan U, Dutta A . NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010; 70(24):10310-20. PMC: 3059213. DOI: 10.1158/0008-5472.CAN-10-2062. View

13.

Shi L, Wang S, Zangari M, Xu H, Cao T, Xu C . Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1(1):22-33. PMC: 2949973. DOI: 10.18632/oncotarget.105. View

14.

Jia L, Li H, Sun Y . Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 2011; 13(6):561-9. PMC: 3114249. DOI: 10.1593/neo.11420. View

15.

Nardiello T, Jungbluth A, Mei A, DiLiberto M, Huang X, Dabrowski A . MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res. 2011; 17(13):4309-19. PMC: 3131419. DOI: 10.1158/1078-0432.CCR-10-1820. View

16.

Lee E, Kim D, Kim J, Yoon Y . Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8. Cancer Res. 2011; 71(21):6827-35. DOI: 10.1158/0008-5472.CAN-10-4356. View

17.

Franke N, Niewerth D, Assaraf Y, van Meerloo J, Vojtekova K, van Zantwijk C . Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 2011; 26(4):757-68. DOI: 10.1038/leu.2011.256. View

18.

McMillin D, Jacobs H, Delmore J, Buon L, Hunter Z, Monrose V . Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012; 11(4):942-51. PMC: 3755358. DOI: 10.1158/1535-7163.MCT-11-0563. View

19.

Spruck C, Strohmaier H, Watson M, Smith A, Ryan A, Krek T . A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell. 2001; 7(3):639-50. DOI: 10.1016/s1097-2765(01)00210-6. View

20.

Chen M, Qi C, Reece D, Chang H . Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Hum Pathol. 2011; 43(6):858-64. DOI: 10.1016/j.humpath.2011.07.013. View